COMPANY

Partner Therapeutics

HQ: Lexington, MA source · partnertx.com ↗

FDA-approved therapeutic company Clinical Phase 2

Partner Therapeutics (PTx) is a commercial biotech. From company website Source · Oct 12, 2026

Keywords: therapeutics NSCLC Harboring NRG1 Fusion Metastatic Castration-resistant Prostate Cancer Solid Tumours Harboring NRG1 Fusion Pancreatic Cancer Harboring NRG1 Fusion NRG1 Fusion COVID-19 SARS-CoV-2 Covid19 SARS-CoV Infection Drug Kinetics Drug Effects on Physiology MCLA-128 zenocutuzumab (MCLA-128)

Location: Lexington, MA · source · Oct 12, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)1FDA records (2 yrs)

Timeline

May 8, 2026 FDA FDA New indication / efficacy supplement: BIZENGRI (zenocutuzumab-zbco) — BLA761352/10, May 8, 2026. Applicant at approval: Partner Therapeutics, Incorporated. source ↗
Dec 2, 2024 Partnership Partnership / licensing announced Dec 2, 2024. Source: company's own press page. source ↗
2024-01 Trial start Phase 2: Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors source ↗
Nov 17, 2022 Trial start Phase 2: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers source ↗
Apr 13, 2022 Trial start Phase 1: Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation source ↗
Apr 27, 2021 Trial start Phase 2: Sargramostim Use in COVID-19 to Recover Patient Health source ↗
Aug 18, 2020 Trial start Phase 2: Study of Sargramostim in Patients With COVID-19 source ↗
2015-01 Trial start Phase 2: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 2 · A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) · NCT02912949

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Dec 2, 2024 Partnership / licensing announced Dec 2, 2024. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT05588609	Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers	Phase 2	Terminated	Nov 17, 2022	Jul 3, 2025 (actual)
NCT02912949	A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)	Phase 2	Active, not recruiting	2015-01	Dec 31, 2026 (estimated)
NCT05284214	Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors	Phase 2	Withdrawn	2024-01	2025-09 (estimated)
NCT04411680	Study of Sargramostim in Patients With COVID-19	Phase 2	Completed	Aug 18, 2020	Mar 2, 2021 (actual)
NCT04707664	Sargramostim Use in COVID-19 to Recover Patient Health	Phase 2	Completed	Apr 27, 2021	Dec 28, 2021 (actual)
NCT05366283	Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation	Phase 1	Completed	Apr 13, 2022	May 27, 2022 (actual)

FDA records (last 2 years)

May 8, 2026 FDA New indication / efficacy supplement: BIZENGRI (zenocutuzumab-zbco) — BLA761352/10, May 8, 2026. Applicant at approval: Partner Therapeutics, Incorporated. source ↗

Connect

See your connections at Partner Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12